505
Views
5
CrossRef citations to date
0
Altmetric
Oncology

Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR

, ORCID Icon, ORCID Icon, , &
Pages 945-951 | Received 14 Apr 2017, Accepted 27 May 2017, Published online: 19 Jun 2017

Figures & data

Figure 1. Cost model.

Figure 1. Cost model.

Figure 2. Study design scheme.

Figure 2. Study design scheme.

Table 1. Clinical inputs from the NET 3-center chart review study for the cost model.

Table 2. Cost inputs from claims data analysis.

Table 3. Clinical inputs for patients under 65 years of age from the Net 3-Center chart review study.

Table 4. Cost reduction associated with CS symptom resolution or improvement: main analysis, healthcare cost.

Table 5. Cost reduction associated with CS symptom resolution or improvement: sensitivity analysis, direct healthcare, and indirect work loss costs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.